Author/Authors :
Grande, Enrique Ramón Y Cajal University Hospital - Department of Medical Oncology, Spain , Capdevila, Jaume Universidad Autónoma de Barcelona - Vall d’Hebrón University Hospital - Department of Medical Oncology, Spain , Díez, Juan José Ramón Y Cajal University Hospital - Department of Endocrinology, Spain , Longo, Federico Ramón Y Cajal University Hospital - Department of Medical Oncology, Spain , Carrato, Alfredo Ramón Y Cajal University Hospital - Department of Medical Oncology, Spain
Abstract :
Anaplastic thyroid cancer (ATC) is a rare disease with an incidence of less than three cases per million of habitants in western countries. ATC accounts for 1‑10% of all tumors derived from the thyroid gland. Classic chemotherapy approach based on platinum and anthracyclines regimens have been considered standard for the last decades. Novel multitarget agents have shown promising responses; however, no positive randomized clinical trials are available up to now. To our knowledge, the case we are presenting here is the first reported case showing clinical and visual activity using sunitinib as a salvage treatment in an ATC patient who was not fit to receive systemic chemotherapy treatment.
